Barclays analyst Carter Gould lowered the firm’s price target on Pfizer to $44 from $49 and keeps an Equal Weight rating on the shares post the Q4 results. The analyst reduced COVID-19 2023 sales expectations and says the greater risk is still to the downside with the end of the public health emergency on the horizon. The firm sees a difficult setup to underwrite rising demand versus current levels.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PFE:
- Pfizer Inc Reported Earnings. Did it Beat Estimates?
- Pfizer CEO: Our best days are still ahead of us
- Pfizer Issues Weak 2023 Guidance; Expects Significant Sales Drop
- Pfizer says incremental share repurchases ‘not high priority at this point’
- Pfizer CFO says increasing investments behind launch products and pipeline
